Serum cystatin C is a better marker of topotecan clearance than serum creatinine

Clinical Cancer Research

Volumn 11, Issue 8, 2005, Pages 3038-3044

  Hoppe, Antje ^a   Séronie Vivien, Sophie ^a   Thomas, Fabienne ^a   Delord, Jean Pierre ^a   Malard, Laurence ^a   Canal, Pierre ^a   Chatelut, Etienne ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C; TOPOTECAN;

ADULT; AGE DISTRIBUTION; AGED; ANALYTIC METHOD; ANALYTICAL ERROR; ARTICLE; BODY SURFACE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DATA ANALYSIS; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG MONITORING; EVALUATION; FEMALE; GLOMERULUS FILTRATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CREATINE; CYSTATINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; TOPOTECAN;

EID: 17144368407     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2086     Document Type: Article

References (20)

1. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
2. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
3. Newman DJ. Cystatin C. Ann Clin Biochem 2002;39: 89-104.
4. Hoek FJ, Kemperman FAW, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003;18: 2024-31.
5. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002;48:699-707.
6. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40: 221-6.
7. Herben VM, Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996;31:85-102.
8. Montazeri A, Boucaud M, Lokiec F, et al. Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemother Pharmacol 2000;46:375-81.
9. Gupta E, Ratain MJ. Camptothecin analogues: topotecan and irinotecan. In: Grochow LB, Ames MM, editors. A clinician's guide to chemotherapy. Pharmamacokinetics and pharmacodynamics. Baltimore: Williams & Wilkins; 1998. p. 435-57.
10. Montazeri A, Culine S, Laguerre B, et al. Individual adaptive dosing of topotecan in ovarian cancer. Clin Cancer Res 2002;8:394-9.
11. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982;8:195-222.
12. Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 2000;18:2459-67.
13. Léger F, Loos WJ, Fourcade J, et al. Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. Br J Cancer 2004;90: 343-7.
14. Grochow LB, Rowinsky EK, Johnson R, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992;20:706-13.
15. Hycamtin. Summary of product characteristics. Smith-Kline Beecham plc. Brentford (UK): 2003.
16. O'Riordan S, Ouldred E, Brice S, Jackson SH, Swift CG. Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine. Br J Clin Pharmacol 2002;53:398-402.
17. Seronie-Vivien S, Galteau MM, Carlier MC, et al. Improving the interlaboratory variation for creatinine serum assay. Ann Biol Clin (Paris) 2004;62:165-75.
18. Coresh J, Eknoyan G, Levey AS. Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration. J Am Soc Nephrol 2002;13:2811-6.
19. Wuyts B, Bernard D, Van den Noortgate N, et al. Reevaluation of formulas for predicting creatinine clearance in adults and children, using compensated creatinine methods. Clin Chem 2003;49:1011-4.
20. Finney H, Newman DJ, Gruber W, et al. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 1997;43:1016-22.